artelo

ChainCatcher news, Nasdaq-listed Solana treasury company Artelo Biosciences announced a public offering of 640,924 shares of common stock at a price of $4.4 per share, raising a total of approximately $3 million. Artelo Biosciences is a clinical pharmaceutical company that has previously announced the official launch of a Solana-based digital asset treasury strategy and has invested part of its capital in purchasing SOL tokens, currently holding 45,883 SOL.

ChainCatcher news, according to GlobeNewswire, clinical-stage pharmaceutical company Artelo Biosciences (NASDAQ: ARTL) announced the completion of a $9.475 million private placement, which will be used to initiate a digital asset reserve strategy centered around Solana (SOL). The company becomes the first publicly traded pharmaceutical enterprise to include SOL in its reserve assets.The private placement includes the issuance of common stock (or pre-funded warrants) at a price of $10.45 per share, as well as two tranches of three-year warrants with exercise prices of $10.20 and $50. The transaction is expected to be completed on August 5, 2025.